categories: MHC (Major Histocompatibility Complex) and Related Antigens (Human)

Mouse Monoclonal to HLA-G

87G (IgG2a)

Product No.	Form	Quantity	Price
11-437-C025	purified	0.025 mg	choose region
11-437-C100	purified	0.1 mg	choose region
12-437-C100	low endotoxin	0.1 mg	choose region
F1-437-C100	Fab fragment	0.1 mg	choose region
1B-437-C025	biotin	0.025 mg	choose region
1B-437-C100	biotin	0.1 mg	choose region
1F-437-C025	FITC	0.025 mg	choose region
1F-437-C100	FITC	0.1 mg	choose region
A4-437-C025	Alexa Fluor® 488	0.025 mg	choose region
A4-437-C100	Alexa Fluor® 488	0.1 mg	choose region
1P-437-C025	PE	0.025 mg	choose region
1P-437-C100	PE	0.1 mg	choose region

- In stock! Ready for immediate despatch

- Manufacture on order

Background

Entrez Gene: 6p21.3

Specificity

The antibody 87G recognizes both membrane-bound and soluble forms of HLA-G (HLA-G1 and HLA-G5). HLA-G belongs to the MHC Class I molecules (MHC Class Ib; nonclassical) and it is expressed on the surface of trophoblast cells.
The antibody 87G blocks interaction of HLA-G with inhibitory receptors.

Immunogen

HLA-B27 transgenic mice were imunized with H-2 identical murine cells transfected with and expressing genes encoding HLA-G and human beta2-microglobulin.

Species Reactivity: Human Negative Species: Mouse Rat	Applications: Flow Cytometry Recommended dilution:2 μg/ml Positive control: JEG-3 human choriocarcinoma epithelial cell line Immunohistochemistry (frozen sections) Recommended dilution: 10 μg/ml Incubation: 20 min at 25°C Positive tissue: extravillous cytotrophoblast ELISA Recommended dilution: 1 μg/ml Positive control: JEG-3 human choriocarcinoma epithelial cell line Application note: The antibody 87G has been tested as the capture antibody in a sandwich ELISA for analysis of human HLA-G in combination with antibody W6/32. Functional Application Application note: The antibody 87G blocks interaction of HLA-G with inhibitory receptors. Usage note: Indicated dilutions are recommended starting points for use of this product. Working concentrations should be determined by the investigator.	General references Lee N. et al.: The membrane-bound and soluble forms of HLA-G bind identical sets of endogenous peptides but differ with respect to TAP association. Immunity 3(5), 591(1995). [Abstract] Product Specific References Riteau B. et al.: HLA-G1 co-expression boosts the HLA class I-mediated NK lysis inhibition. Int Immunol. 13(2), 193 (2001). [Abstract] [Full Text] Sageshima N, Ishitani A, Omura M, Akasaki M, Umekage H, Katabuchi H, Okamura H, Hatake K: Necrotic feature of the trophoblasts lacking HLA-G expression in normal and pre-eclamptic placentas. Am J Reprod Immunol. 2003 Mar;49(3):174-82. [Abstract] Ishitani A. et al.: Protein Expression and Peptide Binding Suggest Unique and Interacting Functional Roles for HLA-E, F and G in Maternal-Placental Immune Recognitions. The Journal of Immunology 171, 1376 (2003). [Abstract] [Full Text] Polakova K, Bandzuchova E, Hofmeister V, Weiss EH, Hutter H, Russ G: Binding analysis of HLA-G specific antibodies to hematopoietic cells isolated from leukemia patients. Neoplasma. 2003;50(5):331-8. [Abstract] Wiendl H: The non-classical MHC molecule HLA-G protects human muscle cells from immune-mediated lysis: implications for myoblast transplantation and gene therapy. Brain. 126(Pt 1), 176 (2003). [Abstract] [Full Text] Menier C, Saez B, Horejsi V, Martinozzi S, Krawice-Radanne I, Bruel S, Le Danff C, Reboul M, Hilgert I, Rabreau M, Larrad ML, Pla M, Carosella ED, Rouas-Freiss N: Characterization of monoclonal antibodies recognizing HLA-G or HLA-E: new tools to analyze the expression of nonclassical HLA class I molecules. Hum Immunol. 2003 Mar;64(3):315-26. [Abstract] Polakova K, Krcova M, Kuba D, Russ G: Analysis of HLA-G expression in malignant hematopoetic cells from leukemia patients. Leuk Res. 2003 Jul;27(7):643-8. [Abstract] Hackmon R, Hallak M, Krup M, Weitzman D, Sheiner E, Kaplan B, Weinstein Y: HLA-G antigen and parturition: maternal serum, fetal serum and amniotic fluid levels during pregnancy. Fetal Diagn Ther. 2004 Sep-Oct;19(5):404-9. [Abstract] Rouas-Freiss N, Moreau P, Ferrone S, Carosella ED: HLA-G proteins in cancer: do they provide tumor cells with an escape mechanism? Cancer Res. 2005 Nov 15;65(22):10139-44. [Abstract] [Full Text] Shobu T, Sageshima N, Tokui H, Omura M, Saito K, Nagatsuka Y, Nakanishi M, Hayashi Y, Hatake K, Ishitani A: The surface expression of HLA-F on decidual trophoblasts increases from mid to term gestation. J Reprod Immunol. 2006 Dec;72(1-2):18-32. [Abstract] LeMaoult J, Caumartin J, Daouya M, Favier B, Le Rond S, Gonzalez A, Carosella ED: Immune regulation by pretenders: cell-to-cell transfers of HLA-G make effector T cells act as regulatory cells. Blood. 2007 Mar 1;109(5):2040-8. [Abstract]

Species Reactivity:

Human

Negative Species:

Mouse
Rat

Applications:

Flow Cytometry
Recommended dilution:2 μg/ml
Positive control: JEG-3 human choriocarcinoma epithelial cell line
Immunohistochemistry (frozen sections)
Recommended dilution: 10 μg/ml
Incubation: 20 min at 25°C
Positive tissue: extravillous cytotrophoblast
ELISA
Recommended dilution: 1 μg/ml
Positive control: JEG-3 human choriocarcinoma epithelial cell line
Application note: The antibody 87G has been tested as the capture antibody in a sandwich ELISA for analysis of human HLA-G in combination with antibody W6/32.
Functional Application
Application note: The antibody 87G blocks interaction of HLA-G with inhibitory receptors.

Usage note:
Indicated dilutions are recommended starting points for use of this product. Working concentrations should be determined by the investigator.

General references

*Lee N. et al.: The membrane-bound and soluble forms of HLA-G bind identical sets of endogenous peptides but differ with respect to TAP association. Immunity 3(5), 591(1995). [Abstract]

Product Specific References

*Riteau B. et al.: HLA-G1 co-expression boosts the HLA class I-mediated NK lysis inhibition. Int Immunol. 13(2), 193 (2001). [Abstract] [Full Text]

*Sageshima N, Ishitani A, Omura M, Akasaki M, Umekage H, Katabuchi H, Okamura H, Hatake K: Necrotic feature of the trophoblasts lacking HLA-G expression in normal and pre-eclamptic placentas. Am J Reprod Immunol. 2003 Mar;49(3):174-82. [Abstract]

*Ishitani A. et al.: Protein Expression and Peptide Binding Suggest Unique and Interacting Functional Roles for HLA-E, F and G in Maternal-Placental Immune Recognitions. The Journal of Immunology 171, 1376 (2003). [Abstract] [Full Text]

*Polakova K, Bandzuchova E, Hofmeister V, Weiss EH, Hutter H, Russ G: Binding analysis of HLA-G specific antibodies to hematopoietic cells isolated from leukemia patients. Neoplasma. 2003;50(5):331-8. [Abstract]

*Wiendl H: The non-classical MHC molecule HLA-G protects human muscle cells from immune-mediated lysis: implications for myoblast transplantation and gene therapy. Brain. 126(Pt 1), 176 (2003). [Abstract] [Full Text]

*Menier C, Saez B, Horejsi V, Martinozzi S, Krawice-Radanne I, Bruel S, Le Danff C, Reboul M, Hilgert I, Rabreau M, Larrad ML, Pla M, Carosella ED, Rouas-Freiss N: Characterization of monoclonal antibodies recognizing HLA-G or HLA-E: new tools to analyze the expression of nonclassical HLA class I molecules. Hum Immunol. 2003 Mar;64(3):315-26. [Abstract]

*Polakova K, Krcova M, Kuba D, Russ G: Analysis of HLA-G expression in malignant hematopoetic cells from leukemia patients. Leuk Res. 2003 Jul;27(7):643-8. [Abstract]

*Hackmon R, Hallak M, Krup M, Weitzman D, Sheiner E, Kaplan B, Weinstein Y: HLA-G antigen and parturition: maternal serum, fetal serum and amniotic fluid levels during pregnancy. Fetal Diagn Ther. 2004 Sep-Oct;19(5):404-9. [Abstract]

*Rouas-Freiss N, Moreau P, Ferrone S, Carosella ED: HLA-G proteins in cancer: do they provide tumor cells with an escape mechanism? Cancer Res. 2005 Nov 15;65(22):10139-44. [Abstract] [Full Text]

*Shobu T, Sageshima N, Tokui H, Omura M, Saito K, Nagatsuka Y, Nakanishi M, Hayashi Y, Hatake K, Ishitani A: The surface expression of HLA-F on decidual trophoblasts increases from mid to term gestation. J Reprod Immunol. 2006 Dec;72(1-2):18-32. [Abstract]

*LeMaoult J, Caumartin J, Daouya M, Favier B, Le Rond S, Gonzalez A, Carosella ED: Immune regulation by pretenders: cell-to-cell transfers of HLA-G make effector T cells act as regulatory cells. Blood. 2007 Mar 1;109(5):2040-8. [Abstract]

For research use only. Not for drug, diagnostic or other use.

Related Products

Mouse IgG2a Isotype Control

Example Data

Fig. 1. Analysis of cytolytical activity

Fig. 1. Analysis of cytolytical activity of human polyclonal NK cells on target melanoma cells. Blocking of HLA-G1 on transfectants with anti-human HLA-G (87G) restored specific lysis.
Target cells: M8 cell line transfected with empty vector (column 1) and with HLA-G1 cDNA (columns 2-6).
Blocking antibodies:
Column 1-2: none
Column 3: Isotype mouse IgG2a control
Column 4: anti-human HLA-G (87G) purified
Column 5: anti-human HLA-G (87G) F(ab´)2 fragment
Column 6: anti-human HLA-G (MEM-G/9; cat. no. 11-292-C100)

PRODUCTS